All In Biotech

Drug Trial Radar · NCT05038800

A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)

A Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of MK-0482 in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

13

Actual

Start

Sep 26, 2021

Primary completion

Dec 11, 2023

Study completion Dec 11, 2023

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study. Part 1 is a dose escalation which will follow an accelerated titration design (ATD) for participants with relapsed/refractory (R/R) AML or CMML. Part 2 is a dose expansion for participants with R/R AML.

Conditions

  • Relapsed or Refractory Acute Myeloid Leukemia
  • Relapsed or Refractory Chronic Myelomonocytic Leukemia

Interventions

  • MK-0482Biological

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced a Dose-Limiting Toxicity (DLT)Time frame: Cycle 1 (up to 21 days)
  2. Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 10 months
  3. Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 4 months

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Roswell Park Cancer Institute ( Site 0006)

    Buffalo, New York

  • University of Texas MD Anderson Cancer Center ( Site 0004)

    Houston, Texas

  • Hadassah Medical Center ( Site 0100)

    Jerusalem, Israel

  • Sheba Medical Center-Hemato Oncology ( Site 0101)

    Ramat Gan, Israel

  • Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 0301)

    Salamanca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.